In order to examine whether customizing treatment could improve outcome in advanced NSCLC patients, we have performed a prospective non-randomized phase II trial of customized treatment based on EGFR mutation status and BRCA1 mRNA expression levels. Here, BRCA1 is linked to non-small cell lung carcinoma.